Also in the MD&A:

"On October 5, 2020, we announced we entered into a cooperative research and development agreement (“CRADA”) with the National Cancer Institute (“NCI”) to develop ZEN-3694 for multiple oncology indications. Under the CRADA, ZEN-3694 will be included in clinical studies in combination with other therapies for cancers with a significant unmet medical need. In the first clinical study under the CRADA, NCI, Zenith, and Bristol Myers Squibb will investigate the combination of ZEN-3694 with checkpoint inhibitors nivolumab and ipilimumab in resistant ovarian cancer. Zenith expects to enter into additional NCI led clinical studies under the CRADA over the coming year to significantly broaden the indications and combination therapies in which ZEN-3694 is explored. The annual cost for Zenith related to each of these collaboration studies (including the cost of ZEN-3694) will be very modest."

But I don't think these CRADA/NCI studies have begun yet.

BDAZ